FTC Continues To Target Pharmaceutical Mergers
The Federal Trade Commission has often stated that merger analysis requires more than a simplistic determination that high market concentration leads to anti-competitive effects.[1] Still, the antitrust agencies have consistently considered...To view the full article, register now.
Already a subscriber? Click here to view full article